环孢菌素A对小鼠T细胞活化影响的血清免疫药理学评价

目的 应用血清免疫药理学技术 ,探讨环孢菌素A(CsA)对T细胞体外活化的影响 ,以进一步揭示CsA免疫调节的分子机制 ,为临床用药提供理论依据。方法 分离小鼠淋巴结细胞 ,分别与CsA、5 %CsA血清预孵后 ,加入多克隆刺激剂继续培养共 2 4h。收获细胞 ,进行双色免疫荧光标记 ,以流式细胞术分析T细胞上CD6 9分子的表达情况。结果 在CsA和 5 %CsA血清作用下 ,ConA活化的T细胞CD6 9表达的百分率分别为 (2 4 15± 3 38) %和 (2 3 6 8±6 89) % ,与相应对照组 [分别为 (6 4 6 7± 5 88) %和 (6 4 35± 10 13) % ]相比较均有显著差异 (P <0 0 1) ;在CsA和5 %CsA血清作用下 ,PDB活化的T细胞CD6 9表达的百分率分别为 (78 86± 7 70 ) %和 (80 0 5± 9 91) % ,与相应对照组 [分别为 (84 79± 6 87) %和 (79 6 8± 4 17) % ]相比较均无显著差异 (P >0 0 5 )。结论 CsA(410nmol/L)和含CsA血清均可强烈抑制ConA刺激的T细胞活化 ,而对PDB刺激的T细胞活化无抑制效应。 5 %CsA血清与CsA单纯药物体外实验的结果相一致 。

放线菌酮对小鼠T细胞活化影响的血清免疫药理评价

目的 :利用淋巴细胞的早期活化标记物CD6 9的表达 ,探讨CHX对T淋巴细胞体外活化的影响。方法 :分离小鼠淋巴结细胞 ,分别与放线菌酮 (CHX)、CHX血清预孵 1h ,加入多克隆刺激剂继续培养 ,总计培养 2 4h后收获细胞 ,进行双色免疫荧光标记 ,以流式细胞术对T细胞的CD6 9分子表达情况进行分析。结果 :在CHX(终浓度10 μmol/L)、CHX血清作用下 ,ConA活化的T细胞CD6 9表达百分率依次为 (12 33± 4 75 ) %、(2 0 39± 6 32 ) % ,与相应对照 [分别为 (6 4 6 7± 3 0 0 ) %、(6 4 35± 10 13) % ]比较均有显著差异 (P <0 0 1) ;相应的 ,药物作用下PDB活化的T细胞CD6 9表达的百分率依次为 (13 0 7± 11 0 5 ) %、(6 10± 4 91) % ,与相应对照 [分别为 (84 79± 6 87) % (79 6 8± 4 17) % ]比较均有显著差异 (P <0 0 1)。结论 :CHX(10 μmol/L)、5 %的CHX血清对ConA、PDB活化的T淋巴细胞均显示了强烈的抑制效应 ,证明T细胞活化过程中CD6 9的表达存在蛋白质的从头合成 ,对“CD6 9表达中CD6 9分子可能储存于细胞浆及其表达的发生并不需要蛋白质的从头合成”这一观点提出质疑。

Study of Effectiveness of Combined Antiallergic Drug Dualler-G

The secretory granules of mast cells contain several mediators, some of which, such as histamine and serotonine, are known to participate in many immune reactions and allergic diseases. Allergic reactions play the leading role in pathogenesis of dermatitis and mechanism of such reactions is based on release of histamine and serotonin. Due to this, the development of drug with both antihistamine and antiseritinine activity was the goal of this study. Drugs with close chemical structure and pharmacological activity were selected from derivates of quinuclidin carbinols. This difference in pharmacological activity of different compounds makes Dualler-G, a new antiallergic drug with antihistamine and antiserotonine activity. The goal of the study was clinical trial of Dualler-G in patients with allergic dermatosis. Obtained data shows that Dualler-G shows high effectiveness in treatment of different types of dermatosis. The effect of Dualler-G, an original antiallergic drug, was evaluated in patients displaying different kinds of dermatosis （urticarea, eczema）. A total of 22 patients diagnosed with dermatosisis were randomized to receive in an open fashion 40 mg of Dualler-G per day, for 2 weeks. Efficacy was assessed according to the common improvement of pathological elements on skin or itching as symptom. Clinical course of patients treated with Dualler-G tended to be significantly better than the patients treated with other antiallergic preparations and the symptoms were significantly correlated in the Dualler-G treated group. These data suggest that Dualler-G provides direct efficacy on the symptoms （skin elements and itching） in patients with different kinds of dermatosis.